You just read:

Sanofi and Regeneron to Present New Data on Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses

News provided by

Sanofi

27 Feb, 2017, 08:30 ET